Front Cover -- MULTIFUNCTIONAL NANOCARRIERS -- MULTIFUNCTIONAL NANOCARRIERS -- Copyright -- Contents -- Contributors -- Editors -- Preface -- 1 -- Nanotechnology: advanced drug-targeting concepts, fundamentals, and strategies -- 1. Introduction -- 2. Approaches for drug targeting -- 2.1 Passive targeting -- 2.2 Active targeting -- 2.2.1 First-order targeting (organ level) -- 2.2.1.1 Drug delivery to the brain -- 2.2.1.2 Drug delivery to lungs -- 2.2.1.2.1 Approaches for pulmonary targeting -- 2.2.1.3 Drug delivery to liver -- 2.2.1.3.1 Approaches for liver targeting -- 2.2.1.3.1.1 Carbohydrate (glycoprotein) receptor-mediated delivery -- 2.2.1.3.1.2 Asialoglycoprotein receptor-mediated delivery -- 2.2.1.3.1.3 Galactose/fucose-specific receptor-mediated delivery -- 2.2.1.3.1.4 Mannose/N-acetylglucosamine receptor-mediated delivery -- 2.2.1.3.1.5 Scavenger receptor-mediated delivery -- 2.2.1.3.1.6 Complement or Fc receptor-mediated delivery -- 2.2.1.3.1.7 LDL receptor-mediated delivery -- 2.2.2 Second-order targeting (cellular targeting) -- 2.2.2.1 Monoclonal antibodies/antibody fragments -- 2.2.2.2 Aptamers -- 2.2.2.3 Peptides -- 2.2.2.4 Folates (RKT) -- 2.2.2.5 Lectins -- 2.2.2.6 Transferrin -- 2.2.2.7 Mannose derivatives -- 2.2.2.7.1 ADEPT (antigen directed enzyme-linked prodrug therapy) -- 2.2.3 Third-order targeting (subcellular/intracellular targeting) -- 2.2.3.1 Endocytosis-based drug delivery -- 2.3 Inverse targeting -- 2.4 Dual targeting -- 2.5 Double targeting -- 2.6 Prodrug approach -- 2.6.1 ADEPT (antibody directed enzyme-linked prodrug therapy) -- 2.6.2 VDEPT (viral directed enzyme-linked prodrug therapy) -- 2.6.3 GDEPT (gene directed enzyme-linked prodrug therapy) -- 3. Fundamental strategies for drug delivery systems -- 3.1 Organic nanocarriers -- 3.1.1 Vesicular carriers -- 3.1.2 Polymeric nanoparticles -- 3.1.3 Lipid nanoparticles.